BioSpace News Archive

IQ-AI Limited, a developer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, and St. Jude Children’s Hospital, have entered into a Data Use Agreement.

Research presented today at the international Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston indicates a blood test can be used to identify people with an increased likelihood of having brain amyloid, a protein that’s a risk factor for developing Alzheimer’s symptoms.

Elevar Therapeutics, Inc. (“Elevar”), today announced that the U.S. Food and Drug Administration (FDA) has granted rivoceranib with orphan drug designation for the treatment of hepatocellular carcinoma (HCC).

Alto Neuroscience today announced the publication of the first ever, most comprehensive data-driven neurological mapping of the mind in the journal Nature Neuroscience.

Cyclica, the partner of choice for data-driven drug discovery, and the Structural Genomics Consortium (SGC), a global public-private partnership dedicated to open science, have collaborated on a project in support of Target 2035, an initiative to discover probe molecules in support of developing medicines for all.

MobileODT, an Israeli Digital Health FemTech company that produces the latest innovation in cervical cancer screening, is proud to announce that their EVA cervical screening technology is supporting a national cervical cancer screening project in India.

Harvest is a time for North American farmers to reflect on the past season’s successes and challenges, while looking ahead to what’s next.

bBioceres Crop Solutions Corp., a fully integrated global provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has received import approval of the Company’s HB4 Wheat flour for animal and human consumption from Brazil’s Ministry of Agriculture, Livestock and Food Supply.

Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the three months ended September 30, 2021 and provided a corporate update.

Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced that Company management will participate in and host one-on-one meetings at the following virtual investor conferences.